The genetic difference between Western and Chinese urothelial cell carcinomas: Infrequent FGFR3 mutation in Han Chinese patients

Oncotarget

Volumn 7, Issue 18, 2016, Pages 25826-25835

  Yuan, Xiaotian ^a,b,c   Liu, Cheng ^d   Wang, Kun ^b,c,d   Liu, Li ^c   Liu, Tiantian ^e   Ge, Nan ^a   Kong, Feng ^a   Yang, Liu ^a   Björkholm, Magnus ^b,c   Fan, Yidong ^a   Zhao, Shengtian ^a   Xu, Dawei ^b,c  

^a THE SECOND HOSPITAL OF SHANDONG UNIVERSITY   (China)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c SHANDONG UNIVERSITY   (China)

^d SHANDONG UNIVERSITY   (China)

^e SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

FGFR3 mutation; Racial disparity; TERT promoter mutation; Upper track urothelial carcinoma; Urothelial bladder carcinoma

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 3; TELOMERASE REVERSE TRANSCRIPTASE; FGFR3 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENETIC DIFFERENCE; GENETIC SCREENING; HAN CHINESE; HUMAN; HUMAN TISSUE; KIDNEY PELVIS CARCINOMA; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PREVALENCE; PROMOTER REGION; RACE DIFFERENCE; SEQUENCE ANALYSIS; TRANSITIONAL CELL CARCINOMA; URETER CARCINOMA; UROTHELIAL BLADDER CARCINOMA; VERY ELDERLY; WESTERN EUROPE; ASIAN CONTINENTAL ANCESTRY GROUP; BLADDER TUMOR; GENETICS; KIDNEY PELVIS; KIDNEY TUMOR; MIDDLE AGED; MUTATION; PATHOLOGY; URETER TUMOR;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, TRANSITIONAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; KIDNEY PELVIS; MALE; MIDDLE AGED; MUTATION; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; URETERAL NEOPLASMS; URINARY BLADDER NEOPLASMS;

EID: 84967261821     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8404     Document Type: Article

References (28)

1. Frantzi M, Makridakis M, Vlahou A. Biomarkers for bladder cancer aggressiveness. Curr Opin Urol. 2012; 22:390-396.
2. Roupret M, Babjuk M, Comperat E, Zigeuner R, Sylvester R, Burger M, Cowan N, Bohle A, Van Rhijn BW, Kaasinen E, Palou J, Shariat SF. European guidelines on upper tract urothelial carcinomas:2013 update. Eur Urol. 2013; 63:1059-1071.
3. van Oers JM, Zwarthoff EC, Rehman I, Azzouzi AR, Cussenot O, Meuth M, Hamdy FC, Catto JW. FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours. Eur Urol. 2009; 55:650-657.
4. Pandith AA, Shah ZA, Siddiqi MA. Oncogenic role of fibroblast growth factor receptor 3 in tumorigenesis of urinary bladder cancer. Urol Oncol. 2013; 31:398-406.
5. Allory Y, Beukers W, Sagrera A, Flandez M, MarquesM, Marquez M, van der Keur KA, Dyrskjot L, Lurkin I, VermeijM, Carrato A, Lloreta J, Lorente JA, et al. Telomerase Reverse Transcriptase Promoter Mutations in Bladder Cancer: High Frequency Across Stages, Detection in Urine, and Lack of Association with Outcome. Eur Urol. 2014; 65:360-366.
6. Hosen I, Rachakonda PS, Heidenreich B, de Verdier PJ, Ryk C,Steineck G, Hemminki K, Kumar R. Mutations in TERT promoter and FGFR3 and telomere length in bladder cancer. Int J Cancer. 2015; 137:1621-1629.
7. Wang K, Liu T, Liu C, Meng Y, Yuan X, Liu L, Ge N, Liu J, Wang C, Ren H, Yan K, Hu S, Xu Z, et al. TERT promoter mutations and TERT mRNA but not FGFR3 mutations are urinary biomarkers in Han Chinese patients with urothelial bladder cancer. Oncologist. 2015; 20:263-269.
8. Wang K, Liu T, Liu L, Liu J, Liu C, Wang C, Ge N, Ren H,Yan K, Hu S, Bjorkholm M, Fan Y, Xu D. TERT promoter mutations in renal cell carcinomas and upper tract urothelial carcinomas. Oncotarget. 2014; 5:1829-1836. doi:10.18632/oncotarget.1829.
9. Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N,Diaz LA, Jr., Friedman AH, Friedman H, Gallia GL, Giovanella BC, Grollman AP, He TC, He Y, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A. 2013; 110:6021-6026.
10. Wang K, Liu T, Ge N, Liu L, Yuan X, Liu J, Kong F, Wang C,Ren H, Yan K, Hu S, Xu Z, Bjorkholm M, et al. TERT promoter mutations are associated with distant metastases in upper tract urothelial carcinomas and serve as urinary biomarkers detected by a sensitive castPCR. Oncotarget. 2014; 5:12428-12439. doi:10.18632/oncotarget.2660.
11. Liu X, Wu G, Hartmann C, Xing M. Highly prevalent TERT promoter mutations in bladder cancer and brain gliobastoma. Cell Cycle. 2013; 12:1637-1638.
12. Rachakonda PS, Hosen I, de Verdier PJ, Fallah M,Heidenreich B, Ryk C, Wiklund NP, Steineck G,Schadendorf D, Hemminki K, Kumar R. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. Proc Natl Acad Sci U S A. 2013; 110:17426-17431.
13. Heidenreich B, Rachakonda PS, Hemminki K, Kumar R. TERT promoter mutations in cancer development. Curr Opin Genet Dev. 2014; 24:30-37.
14. Knowles MA. Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target. World J Urol. 2007; 25:581-593.
15. Bell RJ, Rube HT, Kreig A, Mancini A, Fouse SD, Nagarajan RP, Choi S, Hong C, He D, Pekmezci M, Wiencke JK, Wrensch MR, Chang SM, et al. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer. Science. 2015; 348:1036-1039.
16. Daniel M, Peek GW, Tollefsbol TO. Regulation of the human catalytic subunit of telomerase (hTERT). Gene. 2012; 498:135-146.
17. Kong F, Zheng C, Xu D. Telomerase as a "stemness" enzyme. Sci China Life Sci. 2014; 57:564-570.
18. Cong YS, Wright WE, Shay JW. Human telomerase and its regulation. Microbiol Mol Biol Rev. 2002; 66:407-425.
19. Kompier LC, van Tilborg AA, Zwarthoff EC. Bladder cancer: novel molecular characteristics, diagnostic, and therapeutic implications. Urol Oncol. 2010; 28:91-96.
20. Zieger K, Dyrskjot L, Wiuf C, Jensen JL, Andersen CL, Jensen KM, Orntoft TF. Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors. Clin Cancer Res. 2005; 11:7709-7719.
21. Sfakianos JP, Cha EK, Iyer G, Scott SN, Zabor EC, Shah RH,Ren Q, Bagrodia A, Kim PH, Hakimi AA, Ostrovnaya I, Ramirez R, Hanrahan AJ, et al. Genomic Characterization of Upper Tract Urothelial Carcinoma. Eur Urol. 2015; 68:970-977.
22. van Kessel KE, Kompier LC, de Bekker-Grob EW, Zuiverloon TC, Vergouwe Y, Zwarthoff EC, Steyerberg EW. FGFR3 mutation analysis in voided urine samples to decrease cystoscopies and cost in nonmuscle invasive bladder cancer surveillance: a comparison of 3 strategies. J Urol. 2013; 189:1676-1681.
23. Yoon HH, Shi Q, Alberts SR, Goldberg RM, Thibodeau SN,Sargent DJ, Sinicrope FA. Racial Differences in BRAF/KRAS Mutation Rates and Survival in Stage III Colon Cancer Patients. J Natl Cancer Inst. 2015; 107, DOI:10.1093/jnci/djv186.
24. Jebar AH, Hurst CD, Tomlinson DC, Johnston C, Taylor CF, Knowles MA. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene. 2005; 24:5218-5225.
25. Gui Y, Guo G, Huang Y, Hu X, Tang A, Gao S, Wu R, Chen C,Li X, Zhou L, He M, Li Z, Sun X, et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet. 2011; 43:875-878.
26. Guo G, Sun X, Chen C, Wu S, Huang P, Li Z, Dean M, Huang Y, Jia W, Zhou Q, Tang A, Yang Z, Li X, et al. Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat Genet. 2013; 45:1459-1463.
27. Liu T, Wang N, Cao J, Dinets A, Sofiadis A, Zedenius J, Larsson C, Xu D. The age-and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas. Oncogene. 2014; 33:4978-4984.
28. Wang N, Liu T, Sofiadis A, Juhlin CC, Zedenius J, Hoog A,Larsson C, Xu D. TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA. Cancer. 2014; 120:2965-2979.